2025.09.22 MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) ALSMN-166clinical trials
2025.09.16 MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND ALSMN-166academic conference
2025.07.24 MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials ALSMN-166clinical trials
2025.04.08 First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients ALSMN-166clinical trials
2024.12.05 MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND ALSMN-166academic conference
2024.10.23 MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) ALSMN-166academic conference
2024.09.30 MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) ALSMN-166clinical trials
2024.09.09 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND ALSMN-166academic conference
2024.09.03 MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting ALSMN-166academic conference
2024.08.29 MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition MN-166patents
2024.06.05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer MN-166patents
2024.06.03 MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 GlioblastomaMN-166clinical trials
2024.05.20 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer MN-166patents
2024.05.14 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome MN-166patents
2024.05.07 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) MN-166patents
2024.04.02 MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) GlioblastomaMN-166
2024.03.26 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan MN-166patents
2024.01.17 MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China MN-166patents
2023.12.21 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology MN-166
2023.12.06 MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe MN-166Progressive MSpatents
2023.11.19 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166clinical trials
2023.10.10 MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada ALSMN-166patents
2023.09.27 MediciNova Announces Results of Studies under BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2023.08.17 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166
2023.08.16 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe MN-166patents
2023.06.29 MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting AddictionMN-166clinical trials
2023.05.14 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe MN-166patents
2023.03.09 MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2023.02.20 MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics GlioblastomaMN-166
2023.02.08 MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID MN-166
2023.01.30 MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder AddictionMN-166clinical trials
2023.01.12 MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma GlioblastomaMN-166clinical trials
2023.01.05 MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) MN-166
2022.12.05 MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse MN-166
2022.09.14 MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlioblastomaMN-166
2022.08.16 MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID MN-166
2022.07.21 MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) MN-166
2022.06.30 MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2022.06.08 MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome MN-166clinical trials
2022.04.21 MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research MN-166treatise
2022.04.13 MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome MN-166clinical trials
2022.04.08 MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research AddictionMN-166treatise
2022.02.28 MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal DCMMN-166treatise
2022.02.22 MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs AddictionMN-166treatise
2022.01.27 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe AddictionMN-166patents
2021.12.13 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS ALSMN-166patents
2021.12.10 MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND ALSMN-166academic conference
2021.11.22 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166academic conference
2021.11.11 MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting MN-166academic conference
2021.11.04 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166academic conference
2021.08.30 MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND ALSMN-166academic conference
2021.07.06 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease MN-166patents
2021.06.28 MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166clinical trials
2021.06.21 MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal AddictionMN-166treatise
2021.06.07 MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166clinical trials
2021.05.06 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe ALSMN-166patents
2021.03.10 MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2021.01.19 MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan ALSMN-166patents
2020.12.29 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS MN-166Progressive MSpatents
2020.11.25 MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal MN-166Progressive MStreatise
2020.10.22 MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy CIPNMN-166clinical trials
2020.09.24 MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology CIPNMN-166treatise
2020.08.06 MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention AddictionMN-166academic conference
2020.07.01 MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19 MN-166clinical trials
2020.06.26 MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology GlioblastomaMN-166treatise
2020.04.21 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlioblastomaMN-166patents
2020.04.08 MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) MN-166clinical trials
2020.03.10 MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) MN-166clinical trials
2019.12.05 MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia ALSMN-166academic conference
2019.10.28 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada ALSMN-166patents
2019.07.30 MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia ALSMN-166academic conference
2019.07.12 MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS MN-166Progressive MSclinical trials
2019.06.06 MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS ALSMN-166clinical trials
2019.05.08 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom DCMMN-166clinical trials
2019.05.08 米国神経学会 第71回年次総会（ペンシルベニア州 フィラデルフィア）ポスター “Effect of ibudilast on macular measures in progressive MS: OCT analysis from a phase II trial” MN-166Progressive MSacademic conference
2019.04.16 MN-166（イブジラスト）のALS（筋萎縮性側索硬化症）を適応とするフェーズ2b/3 臨床治験プロトコルのFDA 審査完了のお知らせ ALSMN-166clinical trials
2019.04.02 MN-166 の進行型多発性硬化症を適応とするSPRINT-MS フェーズ 2b 臨床治験サブグループ解析結果のお知らせ MN-166Progressive MSclinical trials
2019.03.25 米国神経学会 第71 回年次総会（ペンシルベニア州 フィラデルフィア）におけるMN-166 の進行型多発性硬化症を適応とするSPRINT-MS フェーズ 2b 臨床治験の新たな解析結果発表のお知らせ MN-166Progressive MSacademic conference
2019.01.09 再発性グリオブラストーマ（神経膠芽腫（GBM））を適応とするMN-166（イブジラスト）とTMZ（テモゾロミド）の併用療法の患者登録開始のおしらせ GlioblastomaMN-166clinical trials
2018.12.08 2018/12/7 英国グラスゴーで開催された第 29回 ALS/MNDALS（筋萎縮性側策硬化症/運動神経疾患 ）国際シンポジウムにおいて、 カロライナ・ヘルスケアシテム神経科学研究の神経筋 /ALS・MDAセンター所長のベンジャミ・リックスブル博士が発表した ALSを適応とするMN -166（イブジラスト）の臨床治験に関するプレゼンテーション資料 ALSMN-166academic conference
2018.09.26 ALS（筋萎縮性側索硬化症）を適応とするMN-166のフェーズ3臨床試験に関するFDAからのポジティブなフィードバック受領のお知らせ ALSMN-166clinical trials
2018.08.30 MN-166の進行型多発性硬化症（SPRINT-MS）フェーズ2b臨床治験結果の New England Journal of Medicine への論文掲載のお知らせ MN-166Progressive MS
2018.08.21 米国国立アルコール摂取障害・依存症研究所（National Institute of Alcohol Abuse and Alcoholism, NIAAA）からのR01研究助成金授与のお知らせ ～MN-166のアルコール摂取障害を対象とするフェーズ2b臨床治験～ AddictionMN-166clinical trials
2018.08.07 MN-166のDegenerative Cervical Myelopathy (変性性頸椎脊椎症)を対象とする ケンブリッジ大学とのフェーズ２/３共同臨床治験の開始のお知らせ ～イギリス国立疾病研究センター National Institute for Health Research (NIHR) からの臨床研究助成金をうけて～ DCMMN-166clinical trials
2018.08.01 第29回 ALS/MND 国際シンポジウムにおける MN-166 のALS を適応とする臨床治験事後解析(ad -hoc)データの発表のお知らせ ALSMN-166clinical trials
2018.04.27 米国神経学会第70回年次総会におけるMN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験での追加臨床データ発表のお知らせ ALSMN-166academic conference
2018.04.24 米国神経学会第70回年次総会プレナリーセッションにおけるMN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験（SPRINT-MS）データ発表のお知らせ MN-166Progressive MSacademic conference
2018.02.19 米国神経学会第70回年次総会におけるMN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験（SPRINT-MS）結果に関する発表のお知らせ MN-166Progressive MSacademic conference
2018.02.02 MN-166進行型多発性硬化症適応のフェーズ2b臨床治験（SPRINT-MS）に関する新たなポジティブデータ発表のお知らせ －イブジラスト治療はプラセボに比べ継続する身体障害進行リスク26％の低下－ MN-166Progressive MSclinical trials
2018.01.31 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験（SPRINT-MS）に関しての学会発表内容のお知らせ MN-166Progressive MSacademic conference
2017.11.02 第28回 ALS/MND 国際シンポジウムにおける、MN-166のALSを適応とする臨床治験に関する口演発表アブストラクト採択のお知らせ ALSMN-166academic conference
2017.10.30 MN-166 の進行型多発性硬化症を適応とするフェーズ 2b 臨床治験(SPRINT-MS)に関して学会発表内容のお知らせ – イブジラストは全脳萎縮進行度を有意に抑制(48%)、安全性・認容性も良好 – MN-166Progressive MSacademic conference
2017.10.26 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験に関して2つの主要評価項目（プライマリーエンドポイント）達成のお知らせ MN-166Progressive MSclinical trials
2017.08.30 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験に関してトップラインデータ発表アブストラクトの第7回ECTRIMS-ACTRIMS合同学術集会レイトブレイキングセッションでの発表採択のお知らせ MN-166Progressive MSacademic conference
2017.06.06 米国臨床腫瘍学会2017年次総会におけるMN-166 のグリオブラストーマ（神経膠芽腫）動物モデルスタディに関する学会発表要旨のお知らせ GlioblastomaMN-166academic conference
2017.05.09 第5回世界脳腫瘍学会連合総会におけるMN-166のグリオブラストーマ（神経膠芽腫）を適応とするスタディに関する演題発表見送りのお知らせ GlioblastomaMN-166academic conference
2017.04.10 American Society of Clinical Oncology (米国臨床腫瘍学会（ASCO)）2017年次総会におけるMN-166 のグリオブラストーマ（神経膠芽腫）動物モデルスタディに関する学会発表のお知らせ GlioblastomaMN-166academic conference
2017.02.28 第5回世界脳腫瘍学会連合総会におけるMN-166のグリオブラストーマ（神経膠芽腫）を適応とするスタディに関するアブストラクト発表採択のお知らせ GlioblastomaMN-166academic conference
2017.02.07 第50回冬季脳研究学会における メタンフェタミン（覚醒剤）依存症を適応とするMN-166のフェーズ1b臨床治験で得られた新たな知見発表のお知らせ AddictionMN-166clinical trials
2016.12.19 MN-166 の進行型多発性硬化症を適応とするフェーズ 2b 臨床治験継続決定のお知らせ ―データ・安全性モニタリング委員会(DSMB)からの勧告を受けて― MN-166Progressive MSclinical trials
2016.10.31 第27回ALS/MND国際シンポジウムにおける、MN-166のALSを適応とする臨床治験に関する口演発表アブストラクト採択のお知らせ ALSMN-166academic conference
2016.06.30 第39回アルコール中毒症研究会議年次総会におけるアルコール依存症を適応とするMN-166の臨床治験の追加解析による知見発表要旨のお知らせ AddictionMN-166academic conference
2016.05.26 第39回アルコール中毒症研究会議年次総会における アルコール依存症を適応とするMN-166の臨床治験の追加解析による知見発表のお知らせ AddictionMN-166academic conference
2016.03.31 MN-166のメタンフェタミン（覚醒剤）依存症を適応とするフェーズ1b臨床治験結果のDrug and Alcohol Dependence への論文掲載のお知らせ AddictionMN-166treatise
2016.02.12 MN-166のメタンフェタミン（覚醒剤）依存症を適応とするフェーズ2臨床治験についてBehavior Biology and Chemistry年次総会シンポジウムでの発表のお知らせ AddictionMN-166academic conference
2016.02.08 MN-166のオピオイド依存症治療を適応とするフェーズ2臨床治験結果についてBehavior Biology and Chemistry年次総会シンポジウムでの発表のお知らせ AddictionMN-166academic conference
2015.12.14 第26回ALS/MND国際シンポジウムにおけるALS（筋萎縮性側索硬化症）を適応とするMN-166の臨床治験中間解析に関するポジティブな結果発表のお知らせ ALSMN-166academic conference
2015.12.10 第54回米国神経精神薬理学会年次総会におけるアルコール依存症を 適応とするMN-166の臨床治験に関するポジティブな結果発表のお知らせ AddictionMN-166academic conference
2015.12.07 MN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験に関する カリフォルニアALS Pac10・リサーチネットワークミーティング第6回年次総会における発表のお知らせ ALSMN-166academic conference
2015.11.10 ALS（筋萎縮性側索硬化症）を適応とするMN-166の効果をバイオマーカーで評価する 新規臨床プロトコルに対するFDAからの承認のお知らせ ALSMN-166clinical trials
2015.11.04 MN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験の中間解析データの第14回NEALS年次総会における発表のお知らせ ALSMN-166academic conference
2015.10.14 MN-166のALS（筋萎縮性側索硬化症）ショウジョウバエモデル前臨床試験データの第26回ALS/MND国際シンポジウムでの発表のお知らせ ALSMN-166academic conference
2015.09.03 MN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験においてNIV（非侵襲的換気補助器）のサポートを受ける進行ALS患者を対象とする修正プロトコルにおける患者登録開始のお知らせ ALSMN-166clinical trials
2015.07.28 MN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験中間解析データに関する第26回ALS/MND国際シンポジウムでの発表のお知らせ ALSMN-166academic conference
2015.06.24 第38回米国アルコール依存症研究学術会議における MN-166のアルコール依存症を適応とするフェーズ2a臨床治験に関する発表内容のお知らせ AddictionMN-166academic conference
2015.06.12 MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験における255名の登録患者の無作為化完了のお知らせ MN-166Progressive MSclinical trials
2015.04.24 第67回米国神経学会における MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験に関する発表内容のお知らせ MN-166Progressive MSacademic conference
2015.03.03 MN-166のオピオイド依存症治療を適応とするフェーズ2a臨床治験に関して第77回アメリカ薬物依存症学会年次総会での発表のお知らせ AddictionMN-166academic conference
2015.02.05 MN-166の進行型多発性硬化症を適応とする臨床治験に関する第67回米国神経学会での発表のお知らせ(Multiple Sclerosis News Today) MN-166Progressive MSacademic conference
0202.12.10 第32回ALS/MND国際シンポジウムにおけるMN-166（イブジラスト）のALSを適応とするフェーズ2b/3臨床治験（COMBAT-ALS）ポスター発表に関するお知らせ ALSMN-166academic conference
0202.11.22 第26回 米国神経腫瘍学会議におけるMN-166（イブジラスト）のグリオブラストーマに関する最新データ発表の詳細に関するお知らせ GlioblastomaMN-166academic conference
